Merck & Co., Inc. (MRK) Stock Analysis and Metrics

Merck

NYSE: MRK

$127.50 ▼ -0.13 (-0.10%)

At close: Jul 17, 2026 · 4:03 PM UTC

Financial Ratios

Market Cap224.23 Bn

P/E25.00

P/S3.41

Div. Yield0.04

ROIC (Qtr)0.00

Total Debt (Qtr)49.12 Bn

Revenue Growth (1y) (Qtr)4.87

Add ratio to table…

About

Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, biologic therapies, vaccines and animal health products. The company operates principally on a product basis and serves both human and animal health markets worldwide. As of December 31, 2025 it employed approximately 75,000 people across its operations.

Merck generates revenue primarily from the sale of human health pharmaceutical and vaccine products as well as animal health pharmaceuticals vaccines and health management solutions. In 2025 total company sales amounted to $65,011 million with pharmaceutical sales of $58,142 million and animal health sales of $6,354 million. Within the pharmaceutical segment the top selling products were Keytruda at $31,680 million Gardasil or Gardasil 9 at $5,233 million Januvia or Janumet at $2,544 million and ProQuad or M-M-R II or Varivax at $2,451 million. The company also earns alliance revenue from collaborations such as Lynparza and Lenvima which contributed $1,450 million and $1,053 million respectively in 2025. Animal health sales were divided between livestock products at $3,896 million and companion animal products at $2,458 million. Other revenues primarily comprising miscellaneous corporate revenues and third party manufacturing arrangements contributed $515 million in 2025.

The company operates through the following segments: Pharmaceutical and Animal Health.

• Pharmaceutical: This segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents sold by prescription for the treatment of human disorders. Human health vaccine products consist of preventive pediatric adolescent and adult vaccines. Key franchises in this segment include oncology led by Keytruda immunology vaccines such as Gardasil ProQuad Vaxneuvance hospital acute care products like Bridion and Prevymis cardiometabolic and respiratory treatments including Winrevair Adempas Verquvo and Ohtuvayre virology agents such as Lagevrio Isentress Delstrigo and Pifeltro neuroscience products like Belsomra and diabetes treatments including Januvia and Janumet. In 2025 the pharmaceutical segment generated $58,142 million in sales.

• Animal Health: This segment discovers develops manufactures and markets a wide range of veterinary pharmaceutical and vaccine products health management solutions and services and digital identification traceability and monitoring products. It serves livestock and companion animal species with products such as antibiotics vaccines parasiticides fertility management tools and nutrition supplements. In 2025 the animal health segment generated $6,354 million in sales with livestock products accounting for $3,896 million and companion animal products for $2,458 million.

Merck holds a leading position in the global pharmaceutical industry competing with other large research based companies generic manufacturers and specialized animal health firms. Its competitive advantages arise from a robust research and development pipeline a diversified portfolio of patented products strategic alliances and collaborations and extensive global manufacturing and distribution capabilities. The company invested heavily in R&D with approximately 24,700 employees engaged in research activities as of December 31, 2025 and maintains a broad clinical pipeline spanning oncology cardiovascular metabolic infectious diseases neuroscience immunology ophthalmology respiratory diseases and vaccines.

The company’s customers include drug wholesalers and retailers hospitals government agencies managed health care providers such as health maintenance organizations and pharmacy benefit managers physicians veterinarians distributors animal producers farmers and pet owners. Specific customer names are not disclosed in the filing.

Investment Thesis

▲ Bull case

Merck's Oncology segment continues to demonstrate robust and diversified growth beyond KEYTRUDA's core performance, with WELIREG sales increasing 43% to $199 million driven by international launches and specific advanced renal cell carcinoma use, while WINREVAIR achieved $525 million in global sales with over 1,600 new U.S. prescriptions, indicating strong early traction in pulmonary arterial hypertension despite being a newer asset. This expansion into complementary therapeutic areas reduces overreliance on any single product and creates multiple near-term revenue inflection points. The company's strategic focus on expanding indications for existing assets—such as KEYTRUDA's 44 FDA-approved indications across 19 tumor types and ongoing priority review filings for ovarian and bladder cancer combinations—maximizes commercial value from established franchises without requiring equivalent R&D investment for entirely new molecules. Furthermore, the announcement of over 20 initial product launches with "blockbuster potential" each, collectively targeting a cumulative commercial opportunity above $70 billion by the mid-2030s, represents a structural shift in Merck's pipeline productivity that the market is underestimating. These launches span diverse areas including sac-TMT (with positive TroFuse-005 endometrial cancer data), enlicitide (with scalable biocatalytic manufacturing advancing PCSK9 inhibitor accessibility), and TERN-701 (from the Terns acquisition), which management explicitly cited as having multibillion-dollar potential in chronic myeloid leukemia. The breadth and stage of these initiatives suggest Merck is transitioning from a KEYTRUDA-centric model to a truly multi-driver growth engine, where near-term catalysts like the August 17 KEYTRUDA+Padcev bladder cancer PDUFA and June 19 WELIREG RCC approval could meaningfully derisk long-term forecasts.
Merck's Animal Health division delivered 6% overall revenue growth with livestock sales up 8% and companion animal sales up 4%, underpinned by structural demand trends rather than temporary factors. Livestock growth was driven by fundamental ruminant and poultry demand coupled with pricing power, while companion animal growth benefited from new launches like NUMELVI (the first and only second-generation JAK inhibitor for allergic dermatitis in dogs) and price increases, partially offset by fewer vet visits—a dynamic that reflects persistent pet ownership trends and innovation-led adoption rather than cyclical weakness. The division's performance is further reinforced by recent regulatory wins, including the Chinese agriculture ministry's approval of Merck's bronchitis vaccine for use in the world's largest chicken-rearing population (over 5 billion birds), which opens a massive, scalable addressable market in a critical protein supply chain. This contrasts with the more mature and competitively intense human pharmaceutical landscape, where Animal Health benefits from less pricing pressure, stronger farmer and veterinarian loyalty, and longer product life cycles. The business's 6% growth, combined with its high-margin profile and reinvestment potential into novel modalities like JAK inhibitors and vaccines for production animals, positions it as a durable, compounding contributor to consolidated earnings that analysts may overlook when focusing solely on pharmaceutical volatility. Furthermore, the integration of Agentforce Life Sciences with Salesforce to create a unified customer engagement platform for veterinarians and farmers enhances operational efficiency, data-driven decision-making, and customer retention—an underappreciated digital transformation that could sustainably improve margins and market share in a fragmented industry.
Merck's strategic investments in AI and data capabilities through the multiyear Google Cloud agreement, expanded Tempus AI collaboration, and Mayo Clinic partnership are creating a systemic advantage in pipeline productivity and clinical success rates that is not yet reflected in near-term financials but will compound over time. The Google Cloud initiative specifically targets scaling agentic AI across the enterprise to accelerate drug discovery, optimize clinical trial design, and improve manufacturing efficiency—capabilities that directly address historical bottlenecks in R&D cycle times and attrition rates. The Tempus AI collaboration focuses on precision oncology, leveraging real-world data to enhance patient stratification and trial outcomes for assets like sac-TMT and I-DXd, while the Mayo Clinic deal provides access to deep genomic and clinical datasets that could identify novel biomarkers or response predictors for oncology and immunology programs. Management explicitly linked these efforts to advancing pipeline innovation with "greater speed and a higher likelihood of ultimately reaching patients," suggesting a tangible uplift in phase transition success rates. Given Merck's scale—over 20 novel mechanisms in its pipeline and more than 2,800 ongoing KEYTRUDA trials—even incremental improvements in AI-driven target identification, patient selection, or trial execution could yield multiple additional approvals or label expansions over the next 3-5 years. The market tends to value AI partnerships superficially as cost-saving measures, but Merck's approach is fundamentally about increasing the probability of technical and regulatory success, which is a higher-value, less-appreciated driver of long-term pipeline value. This is especially critical as the company navigates the patent expiration of KEYTRUDA later this decade, where the ability to rapidly generate and de-risk new assets will determine whether the transition is smooth or disruptive.

Merck's Oncology segment continues to demonstrate robust and diversified growth beyond KEYTRUDA's core performance, with WELIREG sales increasing 43% to $199 million driven by international launches and specific advanced renal cell carcinoma use, while WINREVAIR achieved $525 million in global sales with over 1,600 new U.S. prescriptions, indicating strong early traction in pulmonary arterial hypertension despite being a newer asset. This expansion into complementary therapeutic areas reduces overreliance on any single product and creates multiple near-term revenue inflection points. The company's strategic focus on expanding indications for existing assets—such as KEYTRUDA's 44 FDA-approved indications across 19 tumor types and ongoing priority review filings for ovarian and bladder cancer combinations—maximizes commercial value from established franchises without requiring equivalent R&D investment for entirely new molecules. Furthermore, the announcement of over 20 initial product launches with "blockbuster potential" each, collectively targeting a cumulative commercial opportunity above $70 billion by the mid-2030s, represents a structural shift in Merck's pipeline productivity that the market is underestimating. These launches span diverse areas including sac-TMT (with positive TroFuse-005 endometrial cancer data), enlicitide (with scalable biocatalytic manufacturing advancing PCSK9 inhibitor accessibility), and TERN-701 (from the Terns acquisition), which management explicitly cited as having multibillion-dollar potential in chronic myeloid leukemia. The breadth and stage of these initiatives suggest Merck is transitioning from a KEYTRUDA-centric model to a truly multi-driver growth engine, where near-term catalysts like the August 17 KEYTRUDA+Padcev bladder cancer PDUFA and June 19 WELIREG RCC approval could meaningfully derisk long-term forecasts.
Merck's Animal Health division delivered 6% overall revenue growth with livestock sales up 8% and companion animal sales up 4%, underpinned by structural demand trends rather than temporary factors. Livestock growth was driven by fundamental ruminant and poultry demand coupled with pricing power, while companion animal growth benefited from new launches like NUMELVI (the first and only second-generation JAK inhibitor for allergic dermatitis in dogs) and price increases, partially offset by fewer vet visits—a dynamic that reflects persistent pet ownership trends and innovation-led adoption rather than cyclical weakness. The division's performance is further reinforced by recent regulatory wins, including the Chinese agriculture ministry's approval of Merck's bronchitis vaccine for use in the world's largest chicken-rearing population (over 5 billion birds), which opens a massive, scalable addressable market in a critical protein supply chain. This contrasts with the more mature and competitively intense human pharmaceutical landscape, where Animal Health benefits from less pricing pressure, stronger farmer and veterinarian loyalty, and longer product life cycles. The business's 6% growth, combined with its high-margin profile and reinvestment potential into novel modalities like JAK inhibitors and vaccines for production animals, positions it as a durable, compounding contributor to consolidated earnings that analysts may overlook when focusing solely on pharmaceutical volatility. Furthermore, the integration of Agentforce Life Sciences with Salesforce to create a unified customer engagement platform for veterinarians and farmers enhances operational efficiency, data-driven decision-making, and customer retention—an underappreciated digital transformation that could sustainably improve margins and market share in a fragmented industry.
Merck's strategic investments in AI and data capabilities through the multiyear Google Cloud agreement, expanded Tempus AI collaboration, and Mayo Clinic partnership are creating a systemic advantage in pipeline productivity and clinical success rates that is not yet reflected in near-term financials but will compound over time. The Google Cloud initiative specifically targets scaling agentic AI across the enterprise to accelerate drug discovery, optimize clinical trial design, and improve manufacturing efficiency—capabilities that directly address historical bottlenecks in R&D cycle times and attrition rates. The Tempus AI collaboration focuses on precision oncology, leveraging real-world data to enhance patient stratification and trial outcomes for assets like sac-TMT and I-DXd, while the Mayo Clinic deal provides access to deep genomic and clinical datasets that could identify novel biomarkers or response predictors for oncology and immunology programs. Management explicitly linked these efforts to advancing pipeline innovation with "greater speed and a higher likelihood of ultimately reaching patients," suggesting a tangible uplift in phase transition success rates. Given Merck's scale—over 20 novel mechanisms in its pipeline and more than 2,800 ongoing KEYTRUDA trials—even incremental improvements in AI-driven target identification, patient selection, or trial execution could yield multiple additional approvals or label expansions over the next 3-5 years. The market tends to value AI partnerships superficially as cost-saving measures, but Merck's approach is fundamentally about increasing the probability of technical and regulatory success, which is a higher-value, less-appreciated driver of long-term pipeline value. This is especially critical as the company navigates the patent expiration of KEYTRUDA later this decade, where the ability to rapidly generate and de-risk new assets will determine whether the transition is smooth or disruptive.

▼ Bear case

Merck's Vaccines and Infectious Diseases segment continues to face structural headwinds that are being underestimated, with GARDASIL sales declining 22% to $1.1 billion due to lower demand in China and Japan, compounded by a 10% U.S. decline primarily from CDC purchase timing. While management attributes the U.S. weakness to timing, the persistent weakness in key international markets—particularly China, where public-sector purchasing patterns remain unfavorable—suggests deeper challenges beyond quarterly fluctuations. The HPV vaccine market is becoming increasingly competitive as biosimilars and alternative dosing regimens emerge, and Merck's reliance on national immunization programs makes it vulnerable to shifts in government budget priorities, vaccine hesitancy trends, and evolving epidemiological assessments of HPV-related disease burden. Furthermore, the decline in JANUVIA/JANUMET sales by 28% to $574 million reflects ongoing generic competition in the diabetes franchise, which management did not adequately address as a long-term structural issue rather than a temporary pricing or demand issue. These trends are concerning because Vaccines and Infectious Diseases historically provided a stable, high-margin counterweight to oncology volatility; its erosion reduces portfolio diversification and increases dependence on the success of newer launches like CAPVAXIVE (which, despite 31% growth to $142 million, remains a small fraction of total revenue) and OHTUVAYRE (impacted by CMS reimbursement changes and showing only tentative prescription trend recovery in March). The segment's weakness is not merely cyclical but reflects fundamental challenges in sustaining growth in mature vaccine markets amid intensifying global competition and shifting public health priorities, which could persist for multiple years and offset gains elsewhere.
Merck's guidance assumes a full-year non-GAAP effective tax rate between 23.5% and 24.5%, but this range explicitly includes the impact of the non-tax-deductible one-time charge for the Cidara acquisition, which distorts the true underlying profitability of the core business. By embedding this non-recurring, non-deductible item into the tax rate assumption, Merck is presenting a normalized tax rate that is artificially inflated relative to what the company would earn excluding such charges. This creates a misleading baseline for investors assessing sustainable earnings power, as the adjusted EPS guidance of $5.04–$5.16 already incorporates a $3.62 per share negative impact from Cidara—meaning the true operating performance would need to be significantly stronger to deliver those numbers without the charge. Furthermore, the company's operating expenses guidance range of $36 billion to $36.8 billion excludes the proposed Terns acquisition but does not fully transparently account for the ongoing integration costs, potential goodwill impairments, or R&D overruns that frequently accompany large biotech deals like Cidara ($9 billion charge) and the impending Terns transaction ($5.8 billion one-time R&D charge). Historically, such acquisitions have led to underestimated integration complexity, cultural friction, and delayed realization of synergies, particularly when combining early-stage assets like TERN-701 (which requires significant clinical investment to reach commercialization) with a large, established organization. The market may be underestimating the execution risk and opportunity cost of tying up substantial capital and managerial bandwidth in these transactions, especially when internal pipeline execution remains unproven at scale for many of the 20-plus new growth drivers.
Despite management's optimism about the commercial potential of TERN-701 from the Terns acquisition, the asset remains in early clinical development with only preliminary data showing encouraging molecular response rates, and there is no guarantee it will overcome the significant hurdles in chronic myeloid leukemia (CML), a space dominated by highly effective tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and ponatinib, with deep unmet need primarily limited to patients resistant to multiple lines of therapy. The CML market, while having unmet needs in later-line settings, is relatively small compared to major oncology indications, and achieving best-in-class status requires not only superior efficacy but also advantages in safety, dosing convenience, and resistance profiling—barriers that are exceptionally high given the maturity of existing therapies. Furthermore, the acquisition will impose a $5.8 billion one-time R&D charge (+$2.35 per share) and an ongoing EPS drag of -$0.12 this year from TERN-701 investment and financing, creating a substantial near-term headwind that must be justified by uncertain long-term returns. Management's characterization of TERN-701 as having "multibillion-dollar commercial potential" is speculative at this stage, especially given the high failure rate in oncology acquisitions and the lack of pivotal Phase 3 data. The opportunity cost of allocating nearly $6 billion to an early-stage hematology asset—when that capital could alternatively fund later-stage pipeline assets, increase share buybacks, or accelerate dividends—represents a strategic misstep if the drug fails to deliver differentiated outcomes. This risk is amplified by Merck's stated focus on pursuing deals in the $1 billion to $15 billion range based on compelling science and value alignment, yet the valuation implied by the $5.8 billion charge suggests a high probability-weighted success scenario that may not be supported by current clinical evidence, increasing the potential for future write-downs or strategic misallocation.

Merck's Vaccines and Infectious Diseases segment continues to face structural headwinds that are being underestimated, with GARDASIL sales declining 22% to $1.1 billion due to lower demand in China and Japan, compounded by a 10% U.S. decline primarily from CDC purchase timing. While management attributes the U.S. weakness to timing, the persistent weakness in key international markets—particularly China, where public-sector purchasing patterns remain unfavorable—suggests deeper challenges beyond quarterly fluctuations. The HPV vaccine market is becoming increasingly competitive as biosimilars and alternative dosing regimens emerge, and Merck's reliance on national immunization programs makes it vulnerable to shifts in government budget priorities, vaccine hesitancy trends, and evolving epidemiological assessments of HPV-related disease burden. Furthermore, the decline in JANUVIA/JANUMET sales by 28% to $574 million reflects ongoing generic competition in the diabetes franchise, which management did not adequately address as a long-term structural issue rather than a temporary pricing or demand issue. These trends are concerning because Vaccines and Infectious Diseases historically provided a stable, high-margin counterweight to oncology volatility; its erosion reduces portfolio diversification and increases dependence on the success of newer launches like CAPVAXIVE (which, despite 31% growth to $142 million, remains a small fraction of total revenue) and OHTUVAYRE (impacted by CMS reimbursement changes and showing only tentative prescription trend recovery in March). The segment's weakness is not merely cyclical but reflects fundamental challenges in sustaining growth in mature vaccine markets amid intensifying global competition and shifting public health priorities, which could persist for multiple years and offset gains elsewhere.
Merck's guidance assumes a full-year non-GAAP effective tax rate between 23.5% and 24.5%, but this range explicitly includes the impact of the non-tax-deductible one-time charge for the Cidara acquisition, which distorts the true underlying profitability of the core business. By embedding this non-recurring, non-deductible item into the tax rate assumption, Merck is presenting a normalized tax rate that is artificially inflated relative to what the company would earn excluding such charges. This creates a misleading baseline for investors assessing sustainable earnings power, as the adjusted EPS guidance of $5.04–$5.16 already incorporates a $3.62 per share negative impact from Cidara—meaning the true operating performance would need to be significantly stronger to deliver those numbers without the charge. Furthermore, the company's operating expenses guidance range of $36 billion to $36.8 billion excludes the proposed Terns acquisition but does not fully transparently account for the ongoing integration costs, potential goodwill impairments, or R&D overruns that frequently accompany large biotech deals like Cidara ($9 billion charge) and the impending Terns transaction ($5.8 billion one-time R&D charge). Historically, such acquisitions have led to underestimated integration complexity, cultural friction, and delayed realization of synergies, particularly when combining early-stage assets like TERN-701 (which requires significant clinical investment to reach commercialization) with a large, established organization. The market may be underestimating the execution risk and opportunity cost of tying up substantial capital and managerial bandwidth in these transactions, especially when internal pipeline execution remains unproven at scale for many of the 20-plus new growth drivers.
Despite management's optimism about the commercial potential of TERN-701 from the Terns acquisition, the asset remains in early clinical development with only preliminary data showing encouraging molecular response rates, and there is no guarantee it will overcome the significant hurdles in chronic myeloid leukemia (CML), a space dominated by highly effective tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and ponatinib, with deep unmet need primarily limited to patients resistant to multiple lines of therapy. The CML market, while having unmet needs in later-line settings, is relatively small compared to major oncology indications, and achieving best-in-class status requires not only superior efficacy but also advantages in safety, dosing convenience, and resistance profiling—barriers that are exceptionally high given the maturity of existing therapies. Furthermore, the acquisition will impose a $5.8 billion one-time R&D charge (+$2.35 per share) and an ongoing EPS drag of -$0.12 this year from TERN-701 investment and financing, creating a substantial near-term headwind that must be justified by uncertain long-term returns. Management's characterization of TERN-701 as having "multibillion-dollar commercial potential" is speculative at this stage, especially given the high failure rate in oncology acquisitions and the lack of pivotal Phase 3 data. The opportunity cost of allocating nearly $6 billion to an early-stage hematology asset—when that capital could alternatively fund later-stage pipeline assets, increase share buybacks, or accelerate dividends—represents a strategic misstep if the drug fails to deliver differentiated outcomes. This risk is amplified by Merck's stated focus on pursuing deals in the $1 billion to $15 billion range based on compelling science and value alignment, yet the valuation implied by the $5.8 billion charge suggests a high probability-weighted success scenario that may not be supported by current clinical evidence, increasing the potential for future write-downs or strategic misallocation.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2014)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2014)

Peer Comparison

Create an account

Sign In

Reset Password